Newcastle Confidence in Concept 2016

Lead Research Organisation: Newcastle University


Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.


10 25 50
Description AuToDeCRA 2 - Matching physiology to function: study autologous tolerogenic dendritic cell therapy focus on delivery route
Amount £1,106,921 (GBP)
Funding ID 21811 
Organisation Versus Arthritis 
Start 08/2018 
End 07/2022
Description Medimmune Grant
Amount £20,000 (GBP)
Funding ID 8300264934 
Organisation MedImmune Ltd 
Sector Private
Country United Kingdom
Start 05/2017 
End 05/2022
Description Microglia in the type I interferon system: protective and pathogenic mechanisms
Amount £412,853 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2018 
End 11/2021
Description i4i Innovative diagnostic test for early stage, high risk, melanoma AMLo
Amount £927,143 (GBP)
Funding ID II-LA-0417-20001 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 07/2018 
End 12/2020
Title Modified Complement Proteins and Uses Thereof 
Description The discovery relates to Pre-clinical evaluation of mini-FH derivatives to treat C3G and successful serum half-life extension of our minimal Factor H construct 
IP Reference PCT/GB2018/051087 
Protection Patent application published
Year Protection Granted 2018
Licensed No
Impact It is hoped that this invention will make an impact in the field of kidney transplantation.